Search

Displaying results 3501 - 3510 of 6951 in total
  1. Drug

    Metenkefalin

    go.drugbank.com/drugs/DB12668
    Investigational

    [A203210] Metenkefalin, along with [tridecactide], are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.[L13874,L13877]

    Categories: Experimental Unapproved Treatments for COVID-19, mu-Opioid Receptor Agonist
  2. Drug

    Clemastine

    go.drugbank.com/drugs/DB00283
    ApprovedInvestigational

    An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.

    Categories: Antihistamines for Systemic Use, Antihistamines for Topical Use
  3. Drug

    Ethchlorvynol

    go.drugbank.com/drugs/DB00189
    ApprovedIllicitWithdrawn

    Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.

  4. Drug

    Amolimogene bepiplasmid

    go.drugbank.com/drugs/DB04904
    Investigational

    Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia.

  5. Drug

    Testolactone

    go.drugbank.com/drugs/DB00894
    ApprovedWithdrawn

    An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.

  6. Drug

    Erdosteine

    go.drugbank.com/drugs/DB05057
    ApprovedInvestigational

    It is a _thiol_ derivative produced for the clinical management of chronic obstructive bronchitis, in addition to infective exacerbations of chronic bronchitis.

  7. Drug

    Primidone

    go.drugbank.com/drugs/DB00794
    ApprovedVet approved

    Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 Ma...

  8. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    [L64069] The FDA approved oveporexton on August 5, 2026 for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults. … [L64069] Oveporexton has been recommended for scheduling as a controlled substance, and its final controlled-substance schedule and commercial availability are pending a determination by the Drug Enforcement

    Categories: Orexin receptor agonists
  9. Drug

    mRNA-1283

    go.drugbank.com/drugs/DB22668
    ApprovedInvestigational

    previously approved COVID-19 mRNA vaccines, including the original [Moderna COVID-19 Vaccine], mRNA-1283 encodes only the immunodominant regions (NTD and RBD) of the SARS-CoV-2 spike protein, allowing for … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from

  10. Drug

    Ensifentrine

    go.drugbank.com/drugs/DB16157
    ApprovedInvestigational

    [L50903] On June 26, 2024, the FDA announced the approval of an inhaled product of ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD) in adults, which allows the drug to be